Radiation-Associated Angiosarcoma After Breast Cancer: High Recurrence Rate and Poor Survival Despite Surgical Treatment with R0 Resection

Jojanneke M. Seinen, MD¹, Emelie Styring, MD³, Vincent Verstappen, MD¹, Fredrik Vult von Steyern, MD, PhD³, Anders Rydholm, MD, PhD³, Albert J. H. Suurmeijer, MD, PhD², and Harald J. Hoekstra, MD, PhD¹

¹Department of Surgical Oncology, University of Groningen University Medical Center, Groningen, The Netherlands; ²Department of Pathology, University of Groningen University Medical Center, Groningen, The Netherlands; ³Department of Orthopedics, Lund University, Lund University Hospital, Lund, Sweden

ABSTRACT

Background. Secondary angiosarcoma of the breast is a rare but severe long-term complication of breast cancer treated with breast-conserving surgery and radiotherapy. We characterized a population-based cohort of patients with secondary angiosarcomas from two tertiary hospitals to investigate this complication with respect to surgical treatment and outcome.

Methods. We identified 35 patients with a history of radiation for breast cancer that developed angiosarcoma in the irradiated field from 1990 to 2009. Of these, 31 underwent surgery and were included for analysis.

Results. Angiosarcoma developed after median 7 years (range 3–25 years). R0 resection was obtained in 23 of 31 patients after primary treatment. Local recurrence developed in 19 patients after median 6 months (range 1–89 months). Regional and distant metastases occurred in 13 patients after median 17 months (range 2–50 months); nine which also had local recurrence. Patients whose local recurrence could be operated on had a better survival after treatment than those who were not considered for surgical treatment, median 34 months (range 6–84 months) compared with 6 months (range 5–24 months). The median disease-free survival and disease-specific survival was 16 and 37 months, respectively.

Conclusions. Despite R0 resection, two-thirds of the patients developed a local recurrence. Survival among those with local recurrence was better if the patient could be treated with surgery. Overall, the prognosis was dismal and median DSS was just over 3 years.

Breast-conserving treatment (BCT) with radiotherapy has replaced mastectomy as the standard care for early-stage breast cancer in the last few decades.¹ Radiotherapy is usually administered at a maximum of 50 Gy to the operated area, in some cases with an extra booster of 10–20 Gy to the tumor bed. The incidence of breast cancer is increasing; currently, it affects one in ten women in the western world. Accordingly, more secondary angiosarcomas have been reported, with a cumulative incidence of 0.9 per 1,000 breast cancer cases over 15 years.² The development of secondary angiosarcoma has been linked to radiotherapy and lymphedema.³–⁵

Secondary angiosarcomas after BCT have an observed median latency period of ~4–8 years.⁶–¹⁰ Because of their rarity and seemingly harmless presentation, frequently comprising painless and bruise like skin lesions, both patients and doctors often neglect the initial symptoms and diagnosis is delayed. Patients often have localized, but multifocally growing, disease that is confined to the breast at diagnosis. Surgery is the mainstay of treatment and is usually performed with local resection or mastectomy. The risk of local recurrence and metastasis is high.⁹ There have been several studies of (neo-)adjuvant chemotherapy, but the effects remain unclear.⁹,¹¹,¹²

The poor outcome of secondary angiosarcoma is well known, albeit mainly through numerous case reports.⁸,¹³,¹⁴

Presented at the 64th meeting of the Society of Surgical Oncology, March 2–5, 2011, San Antonio, TX, and at the 35th meeting of the Scandinavian Sarcoma Group, May 4–6, 2011, Malmö, Sweden.

© The Author(s) 2012. This article is published with open access at Springerlink.com

First Received: 17 August 2011; Published Online: 31 March 2012

H. J. Hoekstra, MD, PhD
e-mail: h.j.hoekstra@umcg.nl
Few have looked at the surgical treatment and outcome. We have performed a 2-center retrospective study to characterize the disease with respect to treatment and outcome in a population-based cohort undergoing surgery with curative intent.

METHODS

Cohort

We identified all female patients with histopathologically diagnosed angiosarcoma of the breast in the northern Dutch Health Care Region (1.8 million inhabitants) and the southern Swedish Health Care Region (1.7 million inhabitants). The northern Dutch part of the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA) (since 1971) and the southern Swedish part of the national Swedish Cancer Registry (since 1958), and, in addition, the pathology registry (since 1960) were used to identify all cases within the populations. Patients with breast cancer diagnosed prior to angiosarcoma were selected ($n=50$). Prerequisites used for this study were those proposed by Cahan et al. and modified by Arlen et al.: (1) a sarcoma arising within the field of previous radiotherapy, (2) differing histology between the secondary sarcoma and primary tumor, and (3) at least a 3-year latency period between radiation therapy and development of the sarcoma. Under these criteria, 35 cases were identified from 1990 to 2009. Surgery with curative intent was performed on 31 patients. Data regarding the radiotherapy dose, type of surgery for the angiosarcoma, local recurrence, metastatic disease, and death were obtained from hospital and primary care records.

Patient Characteristics

The median age of patients at the time of breast cancer diagnosis was 59 years (range 42–77 years). As part of breast cancer therapy, radiotherapy was administered at a median dose of 50 Gy (range 45–70 Gy). Nearly one-third of the patients received an extra radiation boost to the tumor bed, resulting in a total dose of 66–70 Gy.

Outcome Measures

The endpoints of this study were disease-free survival (DFS), disease-specific survival (DSS), time to local recurrence, and time to distant metastasis. DFS was defined as the time from start of treatment to local recurrence, distant metastasis, or last follow-up. DSS was defined as time from diagnosis of secondary angiosarcoma to death due to angiosarcoma or last follow-up. Time to local recurrence was defined as the time from treatment to radiological or pathological confirmation of local recurrence. Time to distant metastasis was defined as the time from treatment of the secondary angiosarcoma to radiological or pathological confirmation of metastasis. In the text, surgical margins were defined as R1 (microscopically intralesional) or R0 (microscopically free margin). The data are presented as median and range, unless stated otherwise.

Statistical Analysis

The DFS and DSS were calculated according to the Kaplan–Meier method. All analyses were performed using SPSS software version 18 (released September 9, 2010; SPSS, Chicago, IL).

RESULTS

Angiosarcoma Characteristics

In 13 of 35 patients, angiosarcoma presented as a blue or red discoloration of the skin; in 14 patients, it started with a tumor, and in eight patients, both discoloration and tumor were present. The tumors had a median size of 4 cm (range 1–15 cm), with a multifocal appearance. The median time from the administration of radiotherapy to the development of the sarcoma was 7 years (range 3–25 years), and the median age of the patients when the angiosarcoma was diagnosed was 67 years (range 47–89 years). Of the 35 patients, 31 underwent surgery with curative intent and were included in the survival analysis. The four patients who did not undergo surgery had metastatic or locally advanced disease (Fig. 1).

Primary Treatment

The main surgical approaches used for resection of the primary tumor of the secondary angiosarcoma were local excision of the tumor ($n=7$) (either due to previous mastectomy as part of breast cancer treatment or the local excision was performed outside our tertiary hospitals) and mastectomy ($n=24$) (Table 1). In all cases operated on at the two tertiary centers, the aim was a minimum macroscopic margin of 2 cm. An R0 resection was achieved in 23 patients after primary treatment, seven patients were operated on twice for primary tumor. A total of 16 cases required reconstruction at treatment for the primary tumor, and the choice of reconstruction was tailored to the size of the defect. In 13 cases a split-thickness skin graft was used, in 1 case reconstruction with a pedicled flap of the latissimus dorsi and in 2 cases a combination of both techniques were used for reconstruction.
In addition to surgical treatment for the primary tumor, one patient received neoadjuvant chemotherapy (adriamycin 6 cycles) and one patient received adjuvant radiotherapy (50.4 Gy) after intralesional surgery.

In our series, mastectomy achieved R0 margins at higher rates than local resection (14 of 24 compared with 2 of 7). In addition, in three patients excision of all irradiated tissue was performed based on the radiotherapy field film, achieving R0 resection in 2 cases.

**Local Recurrence**

After a median of 6 months (range 1–89 months), 19 patients developed a local recurrence. Of these, 14 had an initial R0 resection. In patients with local recurrence, 11 patients underwent surgery, which resulted in R0 resection.

![Patient with extensive angiosarcoma in both breasts](image)

**FIG. 1** Patient with extensive angiosarcoma in both breasts

### TABLE 1 Treatment and outcome for primary angiosarcoma disease

|   | Primary operation | Reconstruction | Margins | (neo-) adjuvant treatment | Local recurrence | Metastasis |
|---|------------------|----------------|---------|--------------------------|------------------|-----------|
| 1 | Mastectomy       | STSG           | R0      | No                       | Yes              | No        |
| 2 | Mastectomy       | STSG           | R0<sup>a</sup> | No         | Yes              | No        |
| 3 | Mastectomy       | STSG           | R0      | No                       | No               | No        |
| 4 | Mastectomy       | No             | R0      | No                       | No               | No        |
| 5 | Mastectomy       | No             | R0      | No                       | No               | No        |
| 6 | Mastectomy       | STSG           | R0<sup>a</sup> | No         | Yes              | Yes       |
| 7 | Mastectomy       | No             | R0      | No                       | No               | Yes       |
| 8 | Mastectomy       | STSG           | R0      | No                       | Yes              | No        |
| 9 | Mastectomy       | No             | R0      | No                       | Yes              | No        |
|10 | Local excision   | No             | R0<sup>a</sup> | No         | Yes              | No        |
|11 | Mastectomy       | No             | R0      | No                       | No               | No        |
|12 | Mastectomy       | STSG           | R0      | No                       | Yes              | Yes       |
|13 | Mastectomy       | No             | R0<sup>a</sup> | Radiotherapy | Yes              | No        |
|14 | Local excision   | STSG           | R0      | No                       | No               | No        |
|15 | Mastectomy       | Muscle flap    | R2      | Chemotherapy             | Yes              | Yes       |
|16 | Local excision   | No             | R0<sup>a</sup> | No         | No               | No        |
|17 | Mastectomy       | STSG           | R2      | No                       | Yes              | Yes       |
|18 | Mastectomy       | No             | R2      | No                       | Yes              | No        |
|19 | Local excision   | STSG           | R2      | No                       | No               | Yes       |
|20 | Local excision   | No             | R0      | No                       | Yes              | No        |
|21 | Mastectomy       | STSG           | R1      | No                       | Yes              | No        |
|22 | Mastectomy       | No             | R0      | No                       | Yes              | No        |
|23 | Mastectomy       | No             | R2      | No                       | Yes              | Yes       |
|24 | Mastectomy       | No             | R0      | No                       | Yes              | No        |
|25 | Mastectomy       | STSG           | R0      | No                       | No               | Yes       |
|26 | Mastectomy       | STSG           | R2      | No                       | Yes              | Yes       |
|27 | Mastectomy       | STSG           | R0      | No                       | Yes              | Yes       |
|28 | Mastectomy       | No             | R0      | No                       | No               | No        |
|29 | Mastectomy       | Muscle flap + STSG | R0<sup>a</sup> | No         | No               | No        |
|30 | Local excision   | No             | R2      | No                       | Yes              | Yes       |
|31 | Local excision   | Muscle flap + STSG | R0<sup>a</sup> | No         | No               | No        |

<sup>a</sup> After two surgeries for the primary tumor

STSG split thickness skin graft

In addition to surgical treatment for the primary tumor, one patient received neoadjuvant chemotherapy (adriamycin 6 cycles) and one patient received adjuvant radiotherapy (50.4 Gy) after intralesional surgery.

In our series, mastectomy achieved R0 margins at higher rates than local resection (14 of 24 compared with 2 of 7). In addition, in three patients excision of all irradiated tissue was performed based on the radiotherapy field film, achieving R0 resection in 2 cases.

**Local Recurrence**

After a median of 6 months (range 1–89 months), 19 patients developed a local recurrence. Of these, 14 had an initial R0 resection. In patients with local recurrence, 11 patients underwent surgery, which resulted in R0 resection.
in ten patients. Adjuvant radiotherapy was administered to one patient and adjuvant chemotherapy to one. Of the eight patients not undergoing surgery, one received radiotherapy and one both radiotherapy and chemotherapy (Table 2). The reason for not performing surgery in five of eight patients was concurrent metastasis, of whom four patients received chemotherapy. In the remaining three cases, extensive local disease was the reason not to perform surgery in 2 cases and in 1 case the reason was unknown. Patients who underwent surgery for local recurrence survived a median of 34 months (range 6–84 months) after surgery, compared with 6 months (5–24 months) for those who did not.

**TABLE 2** Treatment and outcome for local recurrence and metastasis

| N | Initial margin primary tumor | Time from treatment to LR (months) | Treatment for LR | Time from treatment to metastasis (months) | Treatment for metastasis | Survival after recurrencea (months) |
|---|-----------------------------|-----------------------------------|------------------|------------------------------------------|--------------------------|-------------------------------------|
| Local recurrence | | | | | | |
| 1 | R0 | 5 | Local excision | – | – | 14 |
| 2 | R0 | 2 | Local excision | – | – | 34 |
| 3 | R0 | 89 | Local excision | – | – | 63 |
| 4 | R0 | 40 | Local excision | – | – | 20 |
| 5 | R0 | 18 | Local excision | – | – | 49 |
| 6 | R0 | 5 | Local excision | – | – | 6 |
| 7 | R0 | 4 | Mastectomy | – | – | 57 |
| 8 | R0 | 22 | Resection based on RT film; ifosfamid, doxorubicin (6 cycles) | – | – | 84 |
| 9 | R0 | 1 | None | – | – | 1 |
| 10 | R1 | 86 | None | – | – | 2 |
| Metastasis | | | | | | |
| 1 | R0 | – | – | 17 (vertebrae) | RT 20 Gy | 20 |
| 2 | R0 | – | – | 2 (lung) | RT 41 Gy | 16 |
| 3 | R0 | – | – | 24 (axillary) | Resection | 29 |
| 4 | R0 | – | – | 50 (cerebral, abdominal) | None | 3 |
| Local recurrence + metastasis | | | | | | |
| 1 | R0 | 6 | – | 23 (lung) | None | 18 |
| 2 | R0 | 8 | Local excision | 18 (vertebrae) | RT 8 Gy | 16 |
| 3 | R1 | 2 | None | 2 (contralateral breast) | Adriamycin (6 cycles); paclitaxel, bevacizumab (5 cycles); cyclofosfamid | 24 |
| 4 | R1 | 12 | None | 8 (axillary) | Resection, RT (dose unknown); Adriamycin (5 cycles); fluorouracil, farmorubicin, cyclofosfamid (4 cycles) | 14 |
| 5 | R0 | 2 | Local excision + RT 30 Gy | 6 (thoracic wall into lungs) | Cisplatin | 9 |
| 6 | R1 | 2 | – | 2 (contralateral breast, sacrum) | None | 1 |
| 7 | R1 | 2 | RT, dose unknown | 2 (cerebral, abdominal) | Cisplatin | 5 |
| 8 | R0 | 18 | None | 17 (axillary, lung) | Resection + RT 45 Gy; doxorubicin + ifosfamid (1 cycle); gemzar, taxotere | 8 |
| 9 | R0 | 12 | Local excision | 41 (axillary) | Resection + RT 50 Gy; doxorubicin + ifosfamid | 55 |

LR local recurrence, RT radiotherapy

a Recurrence: first appearing (local recurrence or distant metastasis)
Metastatic Disease

There were nine patients who developed distant metastatic disease, and four patients developed regional metastatic disease after a median of 17 months (range 2–50 months). Of these patients nine also had a local recurrence. In the four patients with regional metastatic disease, resection of metastasis to lymph nodes was performed, which led to 1 case of R0 resection, 2 cases of R1 resection, and 1 case with unknown margins. Patients with regional metastasis who underwent surgery survived a median of 20 months (range 8–29 months) after surgery, compared with 5 months (range 1–24 months) for those with distant metastasis who did not undergo surgery. Of the 13 patients with metastases, six patients received chemotherapy and six patients underwent radiotherapy (Table 2).

Survival

With a median follow-up of 27 months (range 1–151 months), 21 of 31 patients died; 17 of the deaths were due to angiosarcoma, three due to other diseases, and one patient died of unknown cause. There were ten patients still alive at last follow-up. Of these patients, nine had no evidence of disease after a median follow-up of 53 months (range 10–108 months). The remaining patient had local disease after 7 years. Of the patients with metastasis, one patient was still alive 2.5 years after surgery for regional metastasis. The three patients who underwent excision of all irradiated tissue, based on the radiation field films, with R0 margins were alive after 2, 2.5, and 9 years with no evidence of disease. For the total population, the median DFS and DSS was 16 and 37 months, respectively (Fig. 2a, b).

DISCUSSION

Although secondary angiosarcomas of the breast have an approximate incidence of only 0.9 per 1,000 breast cancer cases, they are important because this disease has a very poor prognosis and is related to a previous medical treatment. In this study, two-thirds of the patients with secondary angiosarcoma presented with the typical blue/red discoloration of the skin, sometimes in combination with palpable tumor. The lesions can be single or multiple nodules, and papules or vesicles. One-third of the patients presented solely with a tumor; therefore, suspicion of secondary angiosarcoma should not rest only upon discoloration of the skin. In any patients with discoloration that does not disappear or tumor development within the radiation field, a needle or open biopsy should be performed. Mammography and/or MRI play only a limited role in diagnostics, but MRI may be slightly better at detecting an angiosarcoma. Since the first case of secondary angiosarcoma of the breast was described in 1987, the prognosis has remained poor, with a median survival of 1–3 years. In our population-based study, we found similar median survivals of 16 and 37 months for DFS and DSS, respectively. Only two of our 35 identified patients presented with metastatic angiosarcoma, both died of the disease within 6 months.

Compared with previously reported population-based studies (Fodor et al. 2006, n = 8; Hodgson et al. 2007, n = 31; and Marchal et al. 1999, n = 9), our cohort had similar median ages at the time of diagnosis of breast cancer (mean 60 years) and secondary angiosarcoma (mean 68 years). To the best of our knowledge, this is the equal largest study (n = 31) published for secondary angiosarcoma developing in the irradiated field, but the largest study focusing on surgical treatment and outcome.
Most secondary angiosarcomas present as localized disease without metastasis. Nevertheless, they are difficult to control and often recur locally. In our series, mastectomy achieved R0 margins at higher rates than local resection. In addition, three patients had mastectomy with resection of all irradiated tissue as primary treatment, R0 margins achieved in 2 cases and are alive after 2–9 years without evidence of disease.

Of the 31 patients who underwent surgery, the primary treatment resulted in R0 resections in 23 patients. Despite this, nearly two-thirds of these patients developed a local recurrence. We believe this to be due to the multifocal growth of angiosarcoma and tumor tissue left behind, even if the surgical margins are considered free. In this study, 11 of 19 patients with a local recurrence were considered eligible for surgery. The five patients with metastasis and three patients with locally extensive disease were not considered suitable for surgical treatment. The patients selected for surgery for local recurrence survived longer than those who did not. This difference we believe is due to different stages of tumor, and hence surgery has not necessarily made the difference. However, we conclude that local recurrence per se should not disqualify from aiming at surgery with curative intent.

In addition, four patients with lymph node metastases underwent surgery. Of these, two patients were without evidence of disease at the last follow-up, more than 2 years after surgery. The other two patients died of tumor after 8 and 14 months because of their angiosarcoma.

In other types of soft tissue sarcoma, adjuvant radiotherapy is frequently applied to improve local control. However, since secondary angiosarcomas develop within a field of radiation, usually the surrounding tissue has already received the maximum dose of radiation. In spite of this, one patient was treated with radiotherapy and initially responded well to therapy. After a few months, however, the disease progressed rapidly. A small single-center study (n = 14) that looked at hyperfractionated and accelerated radiotherapy (HART), with or without surgical resection, found a 64 % 5-year progression-free survival. Other studies reported a good response to (neo-)adjuvant treatment with paclitaxel in some patients. Interpretation of these results is hampered by the limited number of cases and the heterogeneity of the study populations. Therapies targeting angiogenesis through the vascular endothelial growth factor (VEGF) pathway and VEGF receptors (VEGFR) (e.g., sunitinib, sorafenib, and bevacizumab) have been promising in some patients with angiosarcoma; however, they clearly do not benefit a majority of patients.

Another important field of study concerns the dose, extent, and duration of radiotherapy as part of breast-conserving therapy. Studies comparing hypofractionated and conventional fractionation of radiotherapy for breast cancer have been conducted, as have studies investigating radiotherapy for a quadrant of the breast instead of the entire breast. If changes in the dose, extent, and duration of radiotherapy are implemented, the risk of developing secondary angiosarcoma will have to be monitored closely.

In conclusion, the only chance of curative treatment for secondary angiosarcoma is extensive surgery, preferably with resection of all irradiated tissue performed. The rarity of the disease, its complex behavior, and the need for extensive surgery indicates that these tumors should be managed at a tertiary sarcoma center. Despite free margins, two-thirds of the patients in our study developed a local recurrence. Surgical intervention in a selected group improved survival for patients with local recurrence. However, the median DSS was still only 3 years.

OPEN ACCESS This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

REFERENCES

1. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.
2. Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–7.
3. Cozen W, Bernstein L, Wang F, Press MF, Mack TM. The risk of angiosarcoma following primary breast cancer. Br J Cancer. 1999;81:532–6.
4. Schreiber H, Barry FM, Russell WC, Macon WL, 4th, Ponsky JL, Portis WJ. Stewart-Treves syndrome. A lethal complication of postmastectomy lymphedema and regional immune deficiency. Arch Surg. 1979;114:82–5.
5. Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer. 2003;97:1832–40.
6. Marchal C, Weber B, de Lafontan B, Resbeut M, Mignotte H, du Chatelard PP, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys. 1999;44:113–9.
7. Lindford A, Bohlting T, Vaalavirta L, Tenhunen M, Jahkola T, Tukiainen E. Surgical management of radiation-associated cutaneous breast angiosarcoma. J Plast Reconstr Aesthet Surg. 2011;64:1036–42.
8. Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994;102:757–63.
9. Palta M, Morris CG, Grobmyer SR, Copeland EM, 3rd, Mendenhall NP. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. Cancer. 2010;116:1872–8.
10. Styrg F, Fernebro J, Jonsson PE, Ehringer A, Engelau J, Rissler P, et al. Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Res Treat. 2010;122:883–7.
11. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: a multi-disciplinary approach. Cancer. 2003;98:1716–26.

12. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperme-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.

13. Vertse G, Svastics E, Ivanyi A. Postirradiation angiosarcoma of the breast. Magy Seb. 2010;63:164–7.

14. Body G, Sauvanet E, Calais G, Fignon A, Fetissof F, Lansac J. Cutaneous angiosarcoma of the breast following surgery and irradiation of breast adenocarcinoma. J Gynecol Obstet Biol Reprod. (Paris) 1987;16:479–83.

15. Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012;203:156–61.

16. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone; report of 11 cases. Cancer. 1948;1:3–29.

17. Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shah IC. Radiation-induced sarcoma of bone. Cancer. 1971;28:1087–99.

18. West JG, Qureshi A, West JE, Chacon M, Sutherland ML, Haghhighi B, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005;11:115–23.

19. Hodgson NC, Bowen-Wells C, Moffat F, Franceschi D, Avisar E. Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol. 2007;30:570–3.

20. Fodor J, Orosz Z, Szabo E, Sulyok Z, Polgar C, Zaka Z, et al. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature. J Am Acad Dermatol. 2006;54:499–504.

21. Gambini D, Visintin R, Locatelli E, Galassi B, Bareggi C, Runza L, et al. Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Tumori. 2009;95:828–31.

22. Perez-Ruiz E, Ribelles N, Sanchez-Munoz A, Roman A, Marquez A. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol. 2009;48:1078–9.

23. Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22:351–5.

24. START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.

25. START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–41.

26. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.

27. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25:3259–65.

28. Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281–9.

29. Vicini F, Winter K, Straube W, Wong J, Pass H, Rabinovitch R, et al. A phase II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys. 2005;63:1531–7.

30. Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe S, et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–7.